The total number of records retrieved from this search are 52. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_2871	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineOsteosarcoma cell line	Cell lineORD	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result80% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_2872	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineOsteosarcoma cell line	Cell lineORD	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result50% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_2873	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineOsteosarcoma cell line	Cell lineORD	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_2874	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineOsteosarcoma cell line	Cell lineORD	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23816608
IDOV_3177	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result60% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3178	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result50% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3179	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result30% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3180	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result30% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3181	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result30% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3182	Virus nameHerpes simplex virus	Virus strainwild type	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result30% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3183	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result75% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3184	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result50% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3185	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result50% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3186	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result40% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3187	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result40% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3188	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result25% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3189	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result75% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3190	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result50% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3191	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result45% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3192	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result45% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3193	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result40% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3194	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result45% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3195	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result55% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3196	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result25% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3197	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result10% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3198	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result10% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3199	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result10% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3200	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result10% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3201	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.0001 MOI	In-vitro result20% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3202	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.001 MOI	In-vitro result10% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3203	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.01 MOI	In-vitro result10% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3204	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration0.1 MOI	In-vitro result10% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3205	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration1 MOI	In-vitro result10% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3206	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman edwig sarcoma cell line	Cell lineRD-ES	Concentration of cell line90% confluence	In-vitro toxicityNA	AssayCrystal violet staining and absorbance at 595 nm	In-vitro virus concentration10 MOI	In-vitro result10% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3710	Virus nameEnterovirus	Virus strainECHO-7 virus stain Rigvir	Virus genome typeRNA	Virus familyPicornaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell linePublic health england	Origin of cell lineHuman muscle rhabdomyosarcoma cell line	Cell lineRD	Concentration of cell lineNA	In-vitro toxicityNA	AssayLive cell imaging system	In-vitro virus concentration1% virus concentration	In-vitro result94% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29581783
IDOV_3717	Virus nameEnterovirus	Virus strainECHO-7 virus stain Rigvir	Virus genome typeRNA	Virus familyPicornaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell linePublic health england	Origin of cell lineHuman muscle rhabdomyosarcoma cell line	Cell lineRD	Concentration of cell lineNA	In-vitro toxicityNA	AssayLive cell imaging system	In-vitro virus concentration10% virus concentration	In-vitro result98% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29581783
IDOV_5188	Virus nameHerpes simplex virus	Virus strainM002	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copis of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman rhabdosarcoma cell line	Cell lineRD	Concentration of cell line1.5E+3 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration0.1 PFU	In-vitro result100% cell viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27751346
IDOV_5189	Virus nameHerpes simplex virus	Virus strainM002	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copis of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman rhabdosarcoma cell line	Cell lineRD	Concentration of cell line1.5E+3 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration1 PFU	In-vitro result50% cell viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27751346
IDOV_5190	Virus nameHerpes simplex virus	Virus strainM002	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copis of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman rhabdosarcoma cell line	Cell lineRD	Concentration of cell line1.5E+3 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration10 PFU	In-vitro result10% cell viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27751346
IDOV_5191	Virus nameHerpes simplex virus	Virus strainM002	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copis of gamma 34.5 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman rhabdosarcoma cell line	Cell lineRD	Concentration of cell line1.5E+3 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration20 PFU	In-vitro result5% cell viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27751346
IDOV_5387	Virus nameMeasles virus	Virus strainSchwarz vaccine stain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineICCMGR cell bank unit, Iraq	Origin of cell lineHuman rhabdomyosarcoma cell line	Cell lineRD	Concentration of cell line7.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3.4 × 10⁵ pfu	In-vitro result40% cell growth inhibition after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by mitochondrial permeability apoptosis assay	Immunogenic effectNA	Clinical trialNA	PMID27512663
IDOV_5388	Virus nameMeasles virus	Virus strainSchwarz vaccine stain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineICCMGR cell bank unit, Iraq	Origin of cell lineHuman rhabdomyosarcoma cell line	Cell lineRD	Concentration of cell line7.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3.4 × 10⁵ pfu, one fold dilution	In-vitro result56.778% cell growth inhibition after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by mitochondrial permeability apoptosis assay	Immunogenic effectNA	Clinical trialNA	PMID27512663
IDOV_5389	Virus nameMeasles virus	Virus strainSchwarz vaccine stain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineICCMGR cell bank unit, Iraq	Origin of cell lineHuman rhabdomyosarcoma cell line	Cell lineRD	Concentration of cell line7.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3.4 × 10⁵ pfu, two fold dilution	In-vitro result60.493% cell growth inhibition after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by mitochondrial permeability apoptosis assay	Immunogenic effectNA	Clinical trialNA	PMID27512663
IDOV_5390	Virus nameMeasles virus	Virus strainSchwarz vaccine stain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineICCMGR cell bank unit, Iraq	Origin of cell lineHuman rhabdomyosarcoma cell line	Cell lineRD	Concentration of cell line7.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3.4 × 10⁵ pfu, three fold dilution	In-vitro result38.616% cell growth inhibition after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by mitochondrial permeability apoptosis assay	Immunogenic effectNA	Clinical trialNA	PMID27512663
IDOV_5391	Virus nameMeasles virus	Virus strainSchwarz vaccine stain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineICCMGR cell bank unit, Iraq	Origin of cell lineHuman rhabdomyosarcoma cell line	Cell lineRD	Concentration of cell line7.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3.4 × 10⁵ pfu, four fold dilution	In-vitro result31.039% cell growth inhibition after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by mitochondrial permeability apoptosis assay	Immunogenic effectNA	Clinical trialNA	PMID27512663
IDOV_5392	Virus nameMeasles virus	Virus strainSchwarz vaccine stain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineICCMGR cell bank unit, Iraq	Origin of cell lineHuman rhabdomyosarcoma cell line	Cell lineRD	Concentration of cell line7.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3.4 × 10⁵ pfu, five fold dilution	In-vitro result19.801% cell growth inhibition after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by mitochondrial permeability apoptosis assay	Immunogenic effectNA	Clinical trialNA	PMID27512663
IDOV_5393	Virus nameMeasles virus	Virus strainSchwarz vaccine stain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineICCMGR cell bank unit, Iraq	Origin of cell lineHuman rhabdomyosarcoma cell line	Cell lineRD	Concentration of cell line7.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3.4 × 10⁵ pfu, one fold dilution	In-vitro result53.110% cell growth inhibition after 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by mitochondrial permeability apoptosis assay	Immunogenic effectNA	Clinical trialNA	PMID27512663
IDOV_5394	Virus nameMeasles virus	Virus strainSchwarz vaccine stain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineICCMGR cell bank unit, Iraq	Origin of cell lineHuman rhabdomyosarcoma cell line	Cell lineRD	Concentration of cell line7.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3.4 × 10⁵ pfu, two fold dilution	In-vitro result69.954% cell growth inhibition after 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by mitochondrial permeability apoptosis assay	Immunogenic effectNA	Clinical trialNA	PMID27512663
IDOV_5395	Virus nameMeasles virus	Virus strainSchwarz vaccine stain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineICCMGR cell bank unit, Iraq	Origin of cell lineHuman rhabdomyosarcoma cell line	Cell lineRD	Concentration of cell line7.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3.4 × 10⁵ pfu, three fold dilution	In-vitro result53.717% cell growth inhibition after 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by mitochondrial permeability apoptosis assay	Immunogenic effectNA	Clinical trialNA	PMID27512663
IDOV_5396	Virus nameMeasles virus	Virus strainSchwarz vaccine stain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineICCMGR cell bank unit, Iraq	Origin of cell lineHuman rhabdomyosarcoma cell line	Cell lineRD	Concentration of cell line7.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3.4 × 10⁵ pfu, four fold dilution	In-vitro result31.714% cell growth inhibition after 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by mitochondrial permeability apoptosis assay	Immunogenic effectNA	Clinical trialNA	PMID27512663
IDOV_5397	Virus nameMeasles virus	Virus strainSchwarz vaccine stain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineICCMGR cell bank unit, Iraq	Origin of cell lineHuman rhabdomyosarcoma cell line	Cell lineRD	Concentration of cell line7.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3.4 × 10⁵ pfu, five fold dilution	In-vitro result15.174% cell growth inhibition after 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by mitochondrial permeability apoptosis assay	Immunogenic effectNA	Clinical trialNA	PMID27512663
IDOV_5398	Virus nameMeasles virus	Virus strainSchwarz vaccine stain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineICCMGR cell bank unit, Iraq	Origin of cell lineHuman rhabdomyosarcoma cell line	Cell lineRD	Concentration of cell line7.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3.4 × 10⁵ pfu, six fold dilution	In-vitro result5.918% cell growth inhibition after 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by mitochondrial permeability apoptosis assay	Immunogenic effectNA	Clinical trialNA	PMID27512663